Sarah A Meyer1, Paul A Kristiansen2. 1. Meningitis and Vaccine Preventable Diseases Branch, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. Electronic address: smeyer@cdc.gov. 2. Norwegian Institute of Public Health, Oslo, Norway.
The epidemiology of Neisseria meningitidis is dynamic, with risk
of meningococcal disease varying widely by region and depending on a confluence of host,
organism, and environmental factors. Because transmission of N
meningitidis results mainly in asymptomatic carriage, evaluation of
oropharyngeal carriage can be helpful to understand the epidemiology and transmission of
N meningitidis and, in turn, develop strategies for the prevention
and control of meningococcal disease. The bacterium is transmitted through respiratory
droplets and close contact, with transmission increasing in crowded settings such as
military camps, universities, and schools.[1] Household contacts of patients with meningococcal disease have been
shown to be at increased risk of meningococcal carriage and disease in developed
countries, where incidence of meningococcal disease is low and outbreaks infrequent.
However, less is known about household transmission dynamics of N
meningitidis in the unique epidemiological context of the meningitis belt
of sub-Saharan Africa, which is characterised by high rates of endemic disease, annual
outbreaks, and periodic large-scale epidemics, historically due to serogroup A
meningococci.[2]In The Lancet Global Health, Caroline Trotter and
colleagues[3] describe the
importance of household transmission of N meningitidis in the
meningitis belt using data from a series of cross-sectional meningococcal carriage
surveys held across seven countries to describe meningococcal carriage and impact of a
novel meningococcal serogroup A conjugate vaccine (MenAfriVac; Serum Institute of India
PVT, Pune, India). Within the study the investigators recruited a subset of 184
households containing putative N meningitidis carriers due to any
serogroup for longitudinal household carriage surveys carried out over 6 months. 133
households with confirmed index carriers were compared with 51 control households in
which N meningitidis in the putative index carrier was ruled out by
reference testing. 21% (152 of 739) of individuals within index carrier
households subsequently acquired N meninigitidis compared with
9% (35 of 371) of individuals in control households. Due to a paucity of
serogroup A carriers, the impact of MenAfriVac vaccination on carriage acquisition or
loss within households could not be determined. Although the overall carriage
acquisition rate was 2·4% per month (95% CI
1·6–4·0), rates among all age groups were four-to-five-times
higher in households with an index carrier. Overall, the mean duration of carriage was
3·4 months (2·7–4·4). Index carriers were most likely to
be adolescents, with a median age of 12 years, and children younger than 5 years were
most likely to acquire carriage. In index carrier households, most individuals that
subsequently developed carriage acquired the same or a similar strain as the index
carrier, providing evidence for within-household transmission, although external
acquisition was also noted. Further analysis of the strains with next-generation
sequencing will be useful to further differentiate transmission within households versus
external acquisition.Since the progressive introduction of the meningococcal serogroup A conjugate
vaccine in meningitis belt countries via mass vaccination campaigns of 1–29 year
olds starting in 2010, a remarkable effect of the vaccine has been observed.[4] Similar to other conjugate vaccines,
MenAfriVac has demonstrated the ability to markedly reduce serogroup A N
meningitidis carriage prevalence and generate herd immunity, likely
contributing to the near-elimination of serogroup A disease in vaccinated
areas.[5,6] However, epidemics due to other serogroups, such as the
2015 serogroup C epidemics in Niger and Nigeria,[7,8] continue to occur. Thus,
additional strategies for the control of meningococcal disease are needed.The findings of Trotter and colleagues[3] provide further insight into transmission dynamics of N
meningitidis within households in the meningitis belt. However, the low
sensitivity rate of oropharyngeal swabbing (estimated as 57·8%
[95% CI 53·5–62·0] in this study) is a limitation.
Nevertheless, results of this evaluation along with surveillance data suggest that
targeting school-age children and adolescents for vaccination with conjugate vaccines
could provide maximum benefit in terms of direct protection and generation of herd
immunity. Further household carriage evaluations specifically carried out during
epidemics are needed to assess the relative importance of household transmission in the
setting of widespread community transmission. Antibiotic chemoprophylaxis of household
members of meningococcal disease cases is recommended in the meningitis belt outside of
outbreaks,[9] although is rarely
practiced due to resource and logistical constraints. Even though no known cases of
meningococcal disease were reported in households participating in the study from
Trotter and colleagues, the increased rate of subsequent carriage in index households
supports this recommendation and efforts to improve its uptake. Additional evaluation of
carriage among household contacts of a meningococcal case in both outbreak and
non-outbreak settings would provide additional data to inform antibiotic
chemoprophylaxis recommendations in the meningitis belt.Despite the early successes of the MenAfriVac vaccine, endemic disease and
epidemics due to serogroups C, W, and X continue to occur. Additional carriage
evaluations will be helpful to continue to monitor the impact of MenAfriVac on serogroup
A carriage as well as to support the development and evaluation of additional strategies
for the control of meningococcal disease in this region.
Authors: D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood Journal: Lancet Date: 2013-09-12 Impact factor: 79.321
Authors: Fabien V K Diomandé; Mamoudou H Djingarey; Doumagoum M Daugla; Ryan T Novak; Paul A Kristiansen; Jean-Marc Collard; Kadidja Gamougam; Denis Kandolo; Nehemie Mbakuliyemo; Leonard Mayer; James Stuart; Thomas Clark; Carol Tevi-Benissan; William A Perea; Marie-Pierre Preziosi; F Marc LaForce; Dominique Caugant; Nancy Messonnier; Oladapo Walker; Brian Greenwood Journal: Clin Infect Dis Date: 2015-11-15 Impact factor: 9.079
Authors: Bryan van den Broek; Michiel van der Flier; Ronald de Groot; Marien I de Jonge; Jeroen D Langereis Journal: J Innate Immun Date: 2019-07-03 Impact factor: 7.349